Khondrion is a spin-off biopharmaceutical company of Radboud University Medical Center, Nijmegen, The Netherlands (RUMC). Khondrion was founded in 2007 with the aim to make a substantial contribution to the discovery and development of innovative drugs to treat mitochondrial diseases. The company operates a hybrid business model, combining its own drug discovery program with contract research activities. Khondrion has unique cell-based mitochondrial disease models which are especially suited to test efficacy of newly developed compounds.
Prof. Dr. Jan Smeitink
Prof. Dr. Jan Smeitink, is CEO and founder of Khondrion. He also holds a position as professor in Mitochondrial Medicine at the Radboud University Nijmegen Medical Centre (RUN-MC) in The Netherlands, where he coordinates the Nijmegen Centre for Mitochondrial Disorders and the Centre for Systems Biology and Bioenergetics.
Professor Smeitink’s long experience in the field of mitochondrial patho-physiology at the biochemical, cellular and clinical levels will help to interpret the data obtained in SysMedPD and determine the implication of mitochondrial dysfunction in the different cohort of patients included. He will supervise the scientific work carried out by the Khondrion team and will ensure successful collaboration with other partners involved in WP2, WP4, and WP7.
Dr. Julien Beyrath
Dr. Julien Beyrath is Chief Operating Officer at Khondrion.
Julien holds a PhD in molecular and cellular biology with a major in Pharmacology from the University of Strasbourg, France. Prior to working at Khondrion, Julien was researcher at the Centre for Systems Biology and Bioenergetics of the Radboud University Medical Centre, The Netherlands, focusing on the identification of new drug targets for mitochondrial disease. He has expertise in the discovery of drug candidates and their pre-clinical development. Julien is responsible for internal and external research and development programs and manages the day-to-day operations of the Khondrion Laboratories.